ACASTI PHARMA INC.

Highlights Acasti Pharma Inc.

Equities

ACST

CA00430K8656

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-05 pm EDT			5-day change	1st Jan Change
2.89 ^USD	-0.36%		-1.04%	-0.01%

Jun. 27	Acasti Pharma Inc. Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-On Safety Trial	CI
Jun. 21	Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Acasti Pharma Inc. Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-On Safety Trial	Jun. 27	CI
Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	Jun. 21	CI
Acasti Pharma Inc. to Attend BIO International Convention 2024	May. 28	CI
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial	Feb. 01	CI
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal	23-10-24	MT
Acasti Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol	23-07-05	CI
Acasti Pharma Says it has Aligned With FDA Protocol for Phase 3 Trial of GTX-104; Receives New Drug Application Guidance	23-07-05	MT
Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-23	CI
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Second Quarter 2025	23-05-08	CI
Acasti Pharma Inc. to Proceed with Phase 3 Clinical Safety Study for GTX-104	23-04-05	CI
Acasti Pharma Appoints Prashant Kohli as CEO; to Proceed with Phase 3 Clinical Safety Study for GTX-104 Post FDA Feedback	23-04-04	MT
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Acasti Pharma Inc. Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the CompanyÃ†s Drug Candidate for the Treatment of Postherpetic Neuralgia	22-12-22	CI
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Acasti Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer